Skip to main content
Premium Trial:

Request an Annual Quote

Biocartis, Amgen Sign Development Deal for Idylla CDx Biomarker Tests

NEW YORK (GenomeWeb) – Biocartis announced today that it has signed a companion diagnostic development agreement with Amgen to develop CDx biomarker tests on its Idylla platform for a compound Amgen is developing to treat certain solid tumors.

Financial terms of the agreement were not disclosed.

"Today's announcement is [an] important step in the expansion of our CDx portfolio, which should contribute to short term revenue generation and create a strong pipeline of future Idylla CDx biomarker tests," Ulkrik Cordes, Biocartis' executive vice president of companion diagnostics, said in a statement.

This is Biocartis second recent CDx agreement with Amgen. In December, the companies signed an agreement to seek a premarket approval for Biocartis' Idylla KRAS Mutation Test and Idylla NRAS-BRAF Mutation Test with the US Food and Drug Administration, as companion diagnostic tests for Amgen's Vectibix (panitumumab), a monoclonal anti-epidermal growth factor receptor antibody approved to treat certain metastatic colorectal cancer patients with wild-type RAS. The two Idylla biomarker tests allow for the simultaneous detection of 44 clinically relevant colorectal cancer mutations from formalin-fixed paraffin embedded tumor slices, Biocartis said. Amgen said it would provide financial and operational support to Biocartis for the PMA process.

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.